BPC-157
Also called: Body Protection Compound-157, Bepecin, PL 14736, BPC-157 acetate
A synthetic peptide reported to consist of 15 amino acids, described as a fragment of a protein (BPC) originally isolated from human gastric juice. FDA reviews it as a drug substance for compounding. It is not presented here as a dietary supplement.
- Category
- Amino acid and protein
- Forms
- BPC-157 (free base) and BPC-157 acetate; products proposed to FDA included oral capsules, subcutaneous injection, nasal spray, rectal suppository and transdermal cream
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-30
Class 3 Limited studies in people. FDA's 2026 review identified two randomized placebo-controlled rectal-enema studies, reported only as meeting abstracts (32 healthy subjects; 53 with ulcerative colitis), and three uncontrolled studies by injection or infusion (17, 12 and 2 people). No full peer-reviewed RCT publication was found. [1]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CStomach and gut1 topic
CKidneys and bladder1 topic
CBones and joints1 topic
DMuscles and exercise1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Ulcerative colitis (rectal enema) | C | One randomized placebo-controlled study (53 patients; 80 mg enema daily for 2 weeks), reported only as a meeting abstract, found no clear between-group difference; FDA found a lack of evidence to support effectiveness. [1] |
| Chronic knee pain (injection into the joint) | C | In a retrospective study of intra-articular BPC-157 injection for knee pain, 7 of 12 patients reported relief for more than 6 months; the 2025 review rated the available studies level IV and V evidence. [4] |
| Interstitial cystitis (injection into the bladder wall) | C | A single-arm pilot study in 12 women (10 mg injected during cystoscopy) reported complete symptom resolution in 10 and 80% improvement in 2; there was no comparison group. [5] |
| Gastrointestinal and liver injury models (animal studies) | D | In rats, BPC-157-related substances reduced colonic fistulas, liver lesions and gastrointestinal lesions induced by various challenges; FDA notes dose-response, molecular targets and mechanism of action remain unestablished. [1] |
| Musculoskeletal injury models (animal studies) | D | In preclinical models, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries (2025 systematic review of 35 preclinical studies and 1 clinical study). [4] |
Main constituents: BPC-157, a pentadecapeptide (15 amino acids) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Exposures in human studies summarized by FDA: up to 2 mg/kg rectal enema daily for 8 days (24 healthy subjects); 80 mg enema daily for 2 weeks (ulcerative colitis); 2-4 mg intra-articular injection, 1-2 doses (17 people); 10 mg intravesical injection once (12 people); 10 mg then 20 mg intravenous infusion (2 healthy subjects). These are research exposures, not recommendations. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
No LiverTox chapter on BPC-157 was found. FDA (2026): 28-day intramuscular toxicity studies in rats and dogs showed liver-associated signals (increased serum ALT, …
Details and sources - Pregnancy and breastfeedingNo human pregnancy data were found. FDA notes one article reporting no apparent teratogenicity when BPC-157 (free base) was given intramuscularly to …
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)See details
FDA (2026): the nominator did not submit, and FDA did not identify, carcinogenicity studies of BPC-157 (free base) or BPC-157 acetate.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- FDA (2026): there is insufficient clinical safety information to characterize the safety profile of BPC-157; FDA found no studies that gave it to humans by the oral, subcutaneous, nasal or transdermal routes. [1]
- FDA: as a 15-amino-acid peptide given by injection or nasal spray, BPC-157 may pose a significant risk for immunogenicity, potentially amplified by aggregation and peptide-related impurities; no studies formally investigated its immunogenicity. [1]
- FDA's adverse event database (FAERS, through December 4, 2025) had three reports, all with injectable BPC-157: injection-site reaction, shortness of breath, and diffuse hyperpigmentation and gingival darkening (with a BPC-157 plus TB-500 product); causality was unclear. [1]
- FDA: no serious adverse events appear to have been reported in the five small, short human studies, but safety monitoring was mostly unclear; in the healthy-subject enema studies, headache and flatulence were most frequent, with no obvious difference from placebo. [1]
- FDA: 28-day intramuscular studies in rats and dogs were associated with altered clotting measures (aPTT) and liver-associated signals (increased serum ALT, glucose and triglycerides); no carcinogenicity studies were identified. [1]
Identity, quality and standardization
- FDA considers BPC-157 (free base) and BPC-157 acetate not well characterized physically and chemically: naming is inconsistent with USAN, INN or IUPAC standards, and data on identity, purity, peptide-related impurities, aggregates and microbial quality were lacking or inadequate. [1]
- FDA has encountered multiple salts and derivatives, including different active moieties, sold commercially under the same common name; one website mentions BPC-157 and TB-500 multiple-ingredient products 'for research purposes only and not for human or veterinary use'. [1]
- FDA: there is no USP or National Formulary drug substance monograph and no USP dietary supplement monograph for BPC-157 or its acetate. [1]
Regulatory status
- US: FDA's page on bulk drug substances that may present significant safety risks in compounding lists BPC-157 under 'Bulk drug substances nominated but withdrawn' (previously in category 2 of the interim policies), stating: 'Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.' [2]
- US: FDA evaluated BPC-157 (free base) and BPC-157 acetate on its own initiative for the section 503A bulk drug substances list (use evaluated: ulcerative colitis) and concluded: 'we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List', citing poor physicochemical characterization, lack of safety and immunogenicity information, insufficient evidence of effectiveness, and FDA-approved drugs for ulcerative colitis. FDA states it will not issue a final determination until advisory committee input has been considered. [1]
- US: the Pharmacy Compounding Advisory Committee was scheduled to discuss BPC-157-related bulk drug substances on July 23, 2026. [3]
- US: FDA's briefing document states that BPC-157 is not a component of any drug FDA has approved, and notes that BPC-157 is marketed in the United States as an ingredient in dietary supplement products formulated as oral capsules and tablets; the document does not state that BPC-157 is a lawful dietary ingredient. [1]
- Sport: FDA notes that BPC-157 is listed on the World Anti-Doping Agency's prohibited list under non-approved substances (S0). [1]
- Other countries: FDA's search found no approved product containing BPC-157 (free base) or BPC-157 acetate in any country, and no monograph in the European, Japanese or International Pharmacopoeia. [1]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- BPC-157, a pentadecapeptide reported to be a fragment of the BPC protein from human gastric juice Peptide (15 amino acids) [P4]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming BPC-157, Body Protection Compound, Bepecin or PL 14736 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P1]
- FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding, under 'Bulk drug substances nominated but withdrawn' (previously in category 2 of the interim policies). [P5]
- FDA's 2026 evaluation proposed not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List; FDA states BPC-157 is not a component of an FDA-approved drug. [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- FDA (2026): the nominator did not submit, and FDA did not identify, carcinogenicity studies of BPC-157 (free base) or BPC-157 acetate. No IARC or NTP evaluation of BPC-157 was found (IARC Monographs list and NTP technical reports checked 2026-10-30). [P4]
- The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of BPC-157 (checked 2026-10-30). [P2]
Liver (NIH LiverTox)
- No LiverTox chapter on BPC-157 was found. FDA (2026): 28-day intramuscular toxicity studies in rats and dogs showed liver-associated signals (increased serum ALT, glucose and triglyceride levels); longer studies were unavailable. [P4]
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P3]
- Peptide-related impurities and aggregates; microbial quality (bioburden, bacterial endotoxins) — FDA found data on these critical quality attributes lacking or inadequate for BPC-157; solid-phase peptide synthesis may leave process-related impurities, and peptide aggregation is a risk factor for immunogenicity. [P4]
- Identity of the salt form and active moiety (BPC-157 free base versus acetate) — FDA has encountered multiple salts and derivatives, including different active moieties, sold under the same common name. [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- FDA (2026): no human pharmacokinetic data were found after oral, subcutaneous, nasal or transdermal dosing; in two rectal-enema studies BPC-157 was not detected in plasma (or most concentrations were below the assay's lower limit), suggesting no systemic absorption by that route. [P4]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No human pregnancy data were found. FDA notes one article reporting no apparent teratogenicity when BPC-157 (free base) was given intramuscularly to pregnant rats on gestation days 6-15; complete reproductive and developmental studies were not included. [P4]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, retrieved 2026-10-30), 2026-10-30. ecfr.gov
- FDA. Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate) (evaluation memo dated 5/11/2026), 2026-05-11. fda.gov
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Content current as of 04/22/2026), 2026-04-22. fda.gov
Sources
- FDA. Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate) (evaluation memo dated 5/11/2026), 2026-05-11. fda.gov
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Content current as of 04/22/2026), 2026-04-22. fda.gov
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (Content current as of 08/06/2026), 2026-08-06. fda.gov
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025;21(4):485-495 (PMID 40756949), 2025-07-31. pubmed.ncbi.nlm.nih.gov
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024;30(10):12-17 (PMID 39325560), 2024-10. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · L-arginine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.